COMMUNIQUÉS West-GlobeNewswire

Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial
08/04/2024
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts Favorable clinical safety and tolerability profile observed with no dose limiting toxicities [...]
Longeveron Announces Pricing of $5.25 Million Public Offering
08/04/2024
MIAMI, April 08, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related [...]
Smart for Life Releases Corporate Video on Definitive Agreement to Acquire Purely Optimal Nutrition
08/04/2024
CEO of Smart for Life Discusses Profitable Acquisition Expected to Contribute More than $8 Million of Annualized Revenue and Over $1 Million of Adjusted EBITDA MIAMI, April 08, 2024 (GLOBE NEWSWIRE) -- Smart for Life, [...]
Transparency Notifications from Shareholders
08/04/2024
PRESS RELEASE REGULATED INFORMATION 8 April 2024, 06:30 pm CEST Ghent, Belgium – 8 April 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana Medical "), a pioneer in the treatment of fluid [...]
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024
08/04/2024
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length [...]
Merus présente des données précliniques démontrant l’efficacité de Zeno dans le traitement des modèles de cancer avec une forte expression du gène NRG1 lors de la réunion annuelle 2024 de l’AACR
08/04/2024
UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 08 avr. 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS) (« Merus », la « Société », « nous » ou « notre »)/« nos », une société spécialisée dans l’oncologie au stade [...]
Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay at AACR 2024 Expands the Potential of the Platform
08/04/2024
FOSTER CITY, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing a new class of cancer therapies identified [...]
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
08/04/2024
MiNK-215 eliminated MSS colorectal cancer liver metastases in human organoid models MiNK-215 exhibits potent anti-tumor activity through multiple mechanisms including immune activation NEW YORK, April 08, 2024 (GLOBE [...]
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of March 31, 2024
08/04/2024
Disclosure of Share Capital and Voting Rights Outstanding as of March 31, 2024 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]
EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 31 mars 2024
08/04/2024
Nombre total de droits de vote et d’actions composant le capital social au 31 mars 2024 (Conformément à l’article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l’AMF) Charenton- [...]
Sanofi - AGM 30.04.2024 - Availability of Preparatory documents
08/04/2024
COMBINED GENERAL MEETING OF APRIL 30, 2024 AVAILABILITY OF PREPARATORY DOCUMENTS The Company’s shareholders are invited to attend the Combined General Meeting to be held on Thursday April 30, 2024 at 2:30 p.m. (CET) at [...]
Sanofi - AGM 30.04.2024 - Mise à disposition des documents préparatoires
08/04/2024
ASSEMBLEE GENERALE MIXTE DU 30 AVRIL 2024 MODALITES DE MISE A DISPOSITION OU DE CONSULTATION DES DOCUMENTS PREPARATOIRES Les actionnaires de la Société sont invités à participer à l’assemblée générale mixte qui se [...]
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
08/04/2024
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation [...]
Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
08/04/2024
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerce et à l’article 223-16 du Règlement Général de l’ [...]
Mestag Presents Preclinical Data at AACR on its M300 Program, a Conditionally Active LTBR Agonist Designed to Induce Tertiary Lymphoid Structures in Tumors
08/04/2024
CAMBRIDGE, United Kingdom, April 08, 2024 (GLOBE NEWSWIRE) -- Mestag Therapeutics (“Mestag”), a biotech company harnessing new insights into fibroblast-immune interactions, is today presenting data on its M300 program [...]
EssilorLuxottica: First-Quarter 2024 Revenue Conference Call Invitation
08/04/2024
First-Quarter 2024 Revenue Conference Call Invitation Mr STEFANO GRASSI, Chief Financial Officer, and Mr GIORGIO IANNELLA, Head of Investor Relations, have the pleasure of inviting you to our First-Quarter 2024 Revenue [...]
EssilorLuxottica: First-Quarter 2024 Revenue Conference Call Invitation
08/04/2024
First-Quarter 2024 Revenue Conference Call Invitation Mr STEFANO GRASSI, Chief Financial Officer, and Mr GIORGIO IANNELLA, Head of Investor Relations, have the pleasure of inviting you to our First-Quarter 2024 Revenue [...]
Precision Neuroscience Names Verily Co-Founder Brian Otis as Chief Technology Officer
08/04/2024
Otis will lead team developing brain implants for medical use NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Precision Neuroscience Corporation (Precision) today announced that Dr. Brian Otis has joined the company as [...]
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
08/04/2024
Two original papers in Nature highlight the discovery and translational implications of RMC-7977, a RAS(ON) multi-selective tri-complex inhibitor that exhibits unprecedented anti-tumor activity in preclinical models of [...]

Pages